

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 10 November 2014 – On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 30 October 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 30 October 2014 to 28 January 2015.

Since the announcement as of 30 October 2014, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	-		-
30 October 2014	135,000	269.01	36,315,932
31 October 2014	240,000	269.97	64,792,752
3 November 2014	222,000	262.82	58,345,862
4 November 2014	240,000	262.19	62,925,264
5 November 2014	200,000	260.41	52,082,880
6 November 2014	230,000	261.37	60,114,525
7 November 2014	230,000	262.23	60,311,934
Accumulated under the programme	1,497,000		394,889,149

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 239,626 B shares in the period from 30 October 2014 to 7 November

2014. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 49,124,663 B shares of DKK 0.20, corresponding to 1.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 7 November 2014, Novo Nordisk has repurchased a total of 46,520,995 B shares equal to a transaction value of DKK 11,599,264,365.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com

Investors:

Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com

Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com